Saffron
Neurodegenerative Disease
Jinnah Postgraduate Medical CentreUNKNOWNN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
20 Active assets in the Neurodegenerative Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Live Combined Bifidobacterium,Lactobacillus And Enterococcus Capsules Beijing Friendship Hospital | Phase 4 | BB |
Live Combined Bifidobacterium Beijing Friendship Hospital | Phase 4 | BB |
ATORVASTATIN Monash University | Phase 4 | BB |
Pimavanserin Vanderbilt University Medical Center | Phase 4 | BB |
Levodopa Merck Sharp & Dohme LLC | Phase 2 | B |
View all 41 →
Same molecule, other indications
Saffron is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →